BAYZED HEALTH (02609) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 575 million, representing a year-on-year increase of 0.66%. The company recorded a net loss attributable to shareholders of RMB 27.62 million, which expanded by 139.18% compared to the same period last year. Basic loss per share was RMB 0.02.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.